



## Lyrica<sup>®</sup> (pregabalin) – First-time generic

- On July 19, 2019, [Rising Pharmaceuticals](#) launched an [AB-rated](#) generic version of Pfizer's [Lyrica \(pregabalin\)](#) capsules.
  - In addition, [Alkem](#), [Dr. Reddy's](#), [Invagen](#), [MSN Labs](#), [Sciegen](#), and [Teva](#) received FDA approval of AB-rated generic versions of Lyrica capsules on 7/19/2019. Launch plans for these generics are pending.
- Lyrica is indicated for:
  - Management of neuropathic pain associated with diabetic peripheral neuropathy
  - Management of postherpetic neuralgia
  - Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
  - Management of fibromyalgia
  - Management of neuropathic pain associated with spinal cord injury
- Pregabalin is also available as branded oral solution (Lyrica) and extended-release tablets ([Lyrica CR](#)).
  - The oral solution carries the same indications as Lyrica capsules.
  - Lyrica CR is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.
- According to IMS Health, Lyrica had U.S. sales of approximately \$5.5 billion for the 12 months ending March 2019.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.